Objective: Although the route of estrogen administration is known to be an important determinant of the thrombotic risk among postmenopausal women using hormone therapy, recent data have shown that norpregnane derivatives but not micronized progesterone increase venous thromboembolism risk among transdermal estrogens users. However, the differential effects of progesterone and norpregnanes on hemostasis have not yet been investigated.
V enous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is one of the major harmful effects of hormone therapy (HT) use among postmenopausal women. 1, 2 Both observational studies and randomized clinical trials have shown that oral estrogens increased the risk of VTE. 3 However, the EStrogen and THromboEmbolism Risk (ESTHER) Study has recently suggested that transdermal estrogens might be safe with respect to thrombotic risk. 4 In addition, the type of progestogens might also be an important determinant of the thrombotic risk in women using combined estrogens. 5 In this case/control study, as well as in the E3N prospective cohort study, norpregnane derivatives, including nomegestrol acetate and promegestone, could be thrombogenic. By contrast, micronized progesterone and pregnane derivatives were not associated with an increased thrombotic risk. 5, 6 Activated protein C (APC) resistance, associated or not with the presence of the factor V (FV) Leiden mutation, is a well-established risk factor for VTE. 7, 8 Randomized clinical trials have demonstrated that oral but not transdermal estrogens activated blood coagulation 9, 10 and induced an APC resistance state, 10, 11 providing biological support to the differential association of oral and transdermal estrogens with VTE risk. However, whether the progestogen component of HT may play a role in hemostasis remains unclear. Therefore, we investigated the impact of micronized progesterone and norpregnane derivatives on hemostasis parameters in a cross-sectional study among healthy postmenopausal women using transdermal estrogens.
METHODS

Study design
The Study of Norpregnanes on Coagulation was a crosssectional study performed in France in a healthcare center (IPC, Paris) between 2006 and 2007 among healthy postmenopausal volunteer women aged 45 to 70 years who did not use any HT or who were treated with transdermal estrogens combined with either micronized progesterone or norpregnane derivatives. Menopause was defined by amenorrhea for more than 12 months, bilateral ovariectomy, or hysterectomy and age older than 52 years.
Exclusion criteria were anticoagulant treatment, personal history of thrombotic events (self-reported history of deep venous thrombosis or pulmonary embolism), arterial disease (self-reported history of myocardial infarction, coronary insufficiency, stroke, or arterial occlusive disease), or cancer.
Overall, we screened 1,652 women who came voluntarily to the healthcare center during the recruitment period. We excluded women who were not postmenopausal (n = 654), women who were younger than 45 years or older than 70 years (n = 201), women who presented an exclusion criterion (n = 147), and women who used an HT different from transdermal estrogens combined with progesterone or norpregnanes (n = 110). Of the 540 remaining postmenopausal women (470 nonusers, 31 progesterone users, and 39 norpregnane users), 11 women, including 9 nonusers, 1 progesterone user, and 1 norpregnane user, refused to participate in the study (rate of 2% similar between subgroups). The final sample consisted of 529 participants including women treated with transdermal estrogens combined with progesterone (n = 30) or norpregnanes (n = 38) and 461 nonusers. Among the nonusers, one participant was randomly included as a control when we included one user. The final control sample consisted of 41 women.
All participants answered a standardized questionnaire concerning their demographic background, medical history, drug use, and personal habits such as smoking and alcohol consumption.
Blood pressure was assessed three times on the right arm after a 10-minute rest. Height and weight of the participants were systematically measured. Body mass index (BMI) was expressed as the ratio of the weight (kg) to the square of the height (m 2 ).
Women were classified into several groups according to HT use and type. Women who did not use any HT during the last 3 months were included as nonusers. Current users had to be undergoing HT at the time of blood sampling or to have interrupted their treatment less than 3 months previously. Treated women were included as users of transdermal estrogens combined with either micronized progesterone or norpregnane derivatives, including nomegestrol acetate and promegestone. Estrogens were exclusively 17A-estradiol used at a dose of 50 Kg daily. Women who were prescribed micronized progesterone took either 100 mg per day during the entire month or 200 mg per day 12 days a month. Nomegestrol acetate or promegestone was used either during the entire month at the daily dose of 2.5 mg and 250 Kg, respectively, or 12 days a month at an average dose of 5 mg and 500 Kg/day, respectively.
The study protocol was approved by an ethics committee. Written consent was obtained from all participants.
Blood samples
Venous blood was drawn between 8:00 and 10:00 AM after overnight fasting and a 10-minute rest. Cholesterol, triglyceride, and glucose measurements were performed immediately after the blood sample was taken. For coagulation measurements, venous blood (nine volumes) was collected in 5-mL Vacutainer tubes containing 0.105 mol/L trisodium citrate (one volume). Platelet-poor plasma (PPP) was obtained by two centrifugation steps at 2,500g for 15 minutes at 15-C. Small aliquots (400 KL) were transferred into plastic tubes, quickly frozen, and stored at j40-C. Venous blood was also collected in tubes containing 0.084 mL 15% EDTA for DNA extraction.
Hemostasis measurements
Thrombin generation in the presence or absence of APC was measured according to the method described by Hemker et al 12 on a Fluoroscan Ascent fluorometer (Thermolabsystems OY, Helsinki, Finland), using a PPP reagent (a mixture of phospholipids and tissue factor [TF]), a thrombin calibrator, and the fluorogenic substrate FluCa (Thrombinoscope BV, Maastricht, The Netherlands), mainly following the manufacturer's instructions. Briefly, thrombin generation was triggered in 80 KL citrated plasma by the addition of 20 KL PPP reagent and 20 KL of the fluorogenic substrate FluCa in the presence of 5 KL APC 10 Kg/mL (Hyphen Biomed, Neuvilles/Oise, France) or 5 KL NaCl 0.15 M. The final concentration of phospholipids and TF in the mixture was 3.9 KM and 4.8 pM, respectively. Each thrombin generation measurement was calibrated against the fluorescence curve obtained under the same conditions, except for PPP reagent, which was replaced by a thrombin calibrator (Thrombinoscope BV). A pool of plasma samples from healthy participants processed in the laboratory and stored frozen at j80-C was used to normalize the results. Interassay coefficients of variation calculated on the results obtained for the pool in two series of, respectively, seven and six independent runs were less than 10% for the concentration-dependent parameters (endogenous thrombin potential [ETP] and peak height).
For each plasma sample, a normalized APC sensitivity ratio (APCsr ETP ) was calculated by dividing the ratio of the ETP obtained in the presence of APC (ETP +APC ) and in its absence (ETP jAPC ) by the ratio of the ETP +APC and ETP jAPC determined in normal pooled plasma in the same experiment. A high APCsr ETP indicates APC resistance.
Commercially available kits based on enzyme-linked immunosorbent assay methods were used for measuring prothrombin fragment 1 + 2 (Enzygnost F1 + 2 micro; Behring), free TF pathway inhibitor (TFPI) antigen (Asserachrom free TFPI; Stago), and endothelial protein C receptor (EPCR; Asserachrom EPCR; Stago). The other parameters (FVIII, fibrinogen, antithrombin activity, and protein S [PS] activity) were measured using reagents (FVIII-deficient plasmas and
DNA isolation and genotyping
Genomic DNA was extracted from EDTA blood samples using a standard method. Screening for the FV Leiden mutation and the G20210A prothrombin mutation was performed as previously described. 13 
Statistical analysis
On the basis of a previous study, 10 we estimated that 40 participants per group were needed to detect a difference between groups of about two-thirds SD for the PCA resistance distribution with a 5% two-sided level and an 80% statistical power.
The distribution of each parameter was tested for normality. Mean levels are given in arithmetic form. Analysis of variance was used to compare the baseline characteristics of the participants. Multiple comparison procedures were used to assess the differences in hemostatic variables between users and nonusers of HT. Bonferroni correction for multiple testing was applied, and treatments were significantly different at the 0.05 level if there was a P value less than 0.016 within the subgroups. Stepwise multiple linear regression models were used to assess the relative contribution of the hemostatic variables to the prediction of APC sensitivity.
All statistical analyses were performed with the Statistical Analysis System software, version 9.1 (SAS Institute, Inc., Cary, NC). Table 1 shows the general characteristics of women according to HT use. Blood samples were obtained from 108 women, of whom 40 were nonusers, 30 were treated with transdermal estrogens combined with micronized progesterone, and 38 were treated with transdermal estrogens combined with norpregnane derivatives. A large majority of HT users were treated with gel (n = 65), whereas only five women used a patch. Among users of transdermal estrogens combined with norpregnane derivatives, 23 women were treated with nomegestrol acetate and 15 were treated with promegestone.
RESULTS
Overall, 9.3% of women were heterozygous for the FV Leiden mutation or the G20210A prothrombin gene mutation, and the repartition did not significantly differ between groups (P = 0.38). Considering the known influence of these thrombogenic mutations on hemostasis, these women were excluded from the statistical analysis. Regarding the general characteristics of the participants, no significant differences between the groups were found in terms of age, BMI, smoking status, blood pressure, or lipidemia. Women who used transdermal estrogens combined with norpregnane derivatives were specifically prescribed these progestogens because of hyperestrogenic syndromes (breast tenderness [n = 23] or uterus bleeding [n = 12]).
The parameters of thrombin generation according to HT use are given in Table 2 . Intergroup differences were observed for APCsr ETP , ETP +APC , and peak height +APC . Whereas there was no significant change in APCsr ETP between nonusers and women using transdermal estrogens combined with micronized progesterone, women who used transdermal estrogens combined with norpregnane derivatives were significantly less sensitive to APC than were both nonusers and users of transdermal estrogens combined with micronized progesterone (P G 0.01). In addition, the norpregnane-treated group had borderline significantly higher levels of ETP +APC and peak height +APC compared with the other two groups (P G 0.05 for both ETP +APC and peak height +APC ). This pattern reflected the individual correlation of ETP +APC and peak height +APC with APCsr ETP (r = 0.77, P G 0.0001, for ETP +APC , and r = 0.75, P G 0.0001, for peak height +APC ) and the strong correlation between peak height +APC and ETP +APC (r = 0.97, P G 0.0001). Other parameters of thrombin generation did not differ across the different groups. Table 3 shows the results for the other hemostatic parameter measurements according to HT use. Women treated with transdermal estrogens combined with norpregnane derivatives had an increased mean value of prothrombin activation peptide (F1 + 2) compared with nonusers (P G 0.01). Other hemostatic parameters, especially PS activity and free TFPI, did not vary significantly across the different subgroups.
DISCUSSION
Our results show the importance of the progestogen component in determining APC resistance state among postmenopausal women using transdermal estrogens. Although micronized progesterone did not affect hemostasis, norpregnane derivatives might induce APC resistance and might acti-vate blood coagulation. These data provide biological support to the recent findings regarding the increased risk of venous thrombosis among postmenopausal women using transdermal estrogens combined with norpregnane derivatives. 5, 6 The effect of progestogens on VTE risk remains largely unknown among postmenopausal women using HT. However, randomized clinical trials, as well as observational studies, provided some evidence for a more thrombogenic tendency of estrogens associated with progestogens compared with estrogens alone. 3,14<16 In the Women's Health Initiative clinical trials and in the Women's International Study of Long Duration Oestrogen after Menopause trial, there was an increased VTE risk among women receiving opposed estrogens compared with users of estrogen only. Data regarding the differential association of VTE risk with type of progestogens remain scarce, and only two observational studies have so far assessed the thrombotic risk associated with the different pharmacological subgroups of progestogens. 5, 6 Taking into account the difficulties to obtain new clinical data for studying the effect of progestogens on thrombotic risk, assessing their impact on surrogate markers of VTE risk may therefore be useful. In addition, APC resistance has been shown to be a valid marker of VTE risk. 17 Because transdermal estrogens have no or little effect on hemostasis, 11,18<21 assessment of progestogens on blood coagulation seems to be more relevant among postmenopausal women using transdermal estrogen therapy. Previous observational studies and randomized controlled trials have investigated the effect of transdermal estrogens in combination with micronized progesterone, 9,10 medroxyprogesterone acetate, 22<24 or nortestosterone derivatives. 25<27 In randomized controlled trials, transdermal estrogens combined with micronized progesterone did not have an effect either on APC resistance or on prothrombin F1 + 2 concentration, 9, 10 and the present findings are consistent with these previous results. One randomized study showed an increase in prothrombin F1 + 2 concentration among users of transdermal estrogens combined with medroxyprogesterone. 22 In another trial, nortestosterone derivatives used in transdermal estrogen therapy had little or no effect on blood coagulation activation and hemostasis. 25<27 No data are currently available on the effects of norpregnane derivatives on hemostasis among transdermal estrogen users. However, some studies have investigated their impact on association with oral estrogen therapy TFPI, tissue factor pathway inhibitor; F1 + 2, fragment 1 + 2; sEPCR, soluble endothelial protien C receptor. a among postmenopausal women. Although studies have thus far failed to show any changes in levels of hemostatic parameters between users of norpregnane derivatives and users of dydrogesterone, 28<30 recent data suggested that trimegestone, a norpregnane derivative, could have a stronger impact on fibrinolysis compared with dydrogesterone. 31 The mechanisms underlying the effects of transdermal estrogens combined with norpregnane derivatives on hemostasis remain unclear. It has been reported that changes in free PS and TFPI might have important roles in determining the sensitivity of plasma to APC in women receiving oral estrogens. 10, 11, 32 We have previously described no influence of transdermal estrogens combined with micronized progesterone on these parameters. 10, 33 However, whether transdermal estrogens plus norpregnane derivatives have a significant influence on these factors remains unknown. In the present study, the reduced APC sensitivity observed in women using transdermal estrogens combined with norpregnane derivatives was not mediated by PS or free TFPI, the levels of which were not significantly different from those observed among nonusers and among users of transdermal estrogens combined with micronized progesterone. We have also measured plasma levels of the soluble form of EPCR, which was previously reported to inhibit APC anticoagulant activity 34 and might therefore be a candidate to explain differences in APC resistance level. However, no significant intergroup differences have been observed. Future research will therefore be necessary to explain the influence of norpregnane derivatives on APC resistance.
The Study of Norpregnanes on Coagulation is an observational study, and we cannot exclude the possibility that these findings may be due, in part, to bias, especially selection bias. Norpregnane derivatives, either nomegestrol acetate or promegestone, are potent progestogens that have both high antiestrogenic and antigonadotrophic actions. Thus, these progestogens may oppose the estrogen proliferation effect. Norpregnane derivatives are therefore preferentially prescribed to women with hyperestrogenic symptoms (endometrial susceptibility, benign breast diseases, etc). 35<37 Because endogenous estrogen exposure has been positively related to VTE among postmenopausal women, 38 women with a stronger estrogenic climate would be more likely to be at high thrombotic risk. As a consequence, we cannot exclude the possibility that APC resistance, which is observed among women using norpregnane derivatives, might also be related to a hypercoagulability state because of the presence of a hyperestrogenic status rather than exclusively to the deleterious effect of these progestogens on hemostasis. Therefore, this bias could, in part, explain the increased level of blood coagulation activation and APC resistance among users of norpregnane derivatives. Another selection bias could also occur among users of progesterone, which is preferentially used by obese women because of its neutral impact on cardiovascular risk factors. However, in our study, women using progesterone had a similar average BMI than did control women, and means of hemostatic parameters were adjusted for BMI. Finally, a limitation of our study relates to the extrapolation of results. Our data on norpregnanes were restricted to nomegestrol acetate and promegestone, and the results cannot be extrapolated to other norpregnane derivatives, including trimegestone.
CONCLUSIONS
Our results emphasize the importance of the progestogen components in HT on plasma sensitivity to APC resistance and other hemostatic variables. They may serve to provide a biological support to the differences in thrombotic risk by different progestogen varieties. Taken together, both clinical 4,5 and biological 9,10 data suggest that transdermal estrogens combined with micronized progesterone might be safe with respect to thrombotic risk. However, these findings need to be confirmed in randomized controlled trials.
